# US 2014/0154250 A1 · Single-chain multivalent binding proteins with effector function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154250 A1
- Document ID: US20140154250A1
- Status: Published application
- Kind: A1
- Application number: 13/815,720
- Filed: 2013-03-15
- Published: 2014-06-05
- Earliest claimed: 2006-06-12
- Assignees: Emergent Product Development Seattle, LLC
- Applicants: Emergent Product Development Seattle, LLC
- Inventors: PETER ARMSTRONG THOMPSON; JEFFREY A. LEDBETTER; MARTHA SUSAN HAYDEN-LEDBETTER; WILLIAM BRADY
- Web page: https://patentgrep.com/patent/US20140154250A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins.

## Claims

### Claim 1

A single-chain multivalent binding protein comprising from amino-terminus to carboxyl-terminus:
(a) a first binding domain comprising a first light chain immunoglobulin variable region (VL1) and a first heavy chain immunoglobulin variable region (VH1), wherein said variable regions are positioned in a VH1-VL1 or a VL1-VH1 orientation and separated by a first peptide linker of 2-50 amino acids;
(b) an immunoglobulin hinge domain;
(c) an immunoglobulin CH2 domain
(d) an immunoglobulin CH3 domain
(e) a scorpion linker; and
(f) a second binding domain comprising a second light chain immunoglobulin variable region (VL2) and a second heavy chain immunoglobulin variable region (VH2), wherein said variable regions are positioned in a VH2-VL2 or a VL2-VH2 orientation and separated by a second peptide linker of 2-50 amino acids,
wherein the multivalent binding protein is capable of forming a dimer in solution.

### Claim 2 (depends on 1)

The binding protein of claim 1, wherein VL1 and VH1 are from the same immunoglobulin.

### Claim 3 (depends on 1)

The binding protein of claim 1, wherein VL1 and VH1 are from different immunoglobulins.

### Claim 4 (depends on 1)

The binding protein of claim 1, wherein VL2 and VH2 are from the same immunoglobulin.

### Claim 5 (depends on 1)

The binding protein of claim 1, wherein VL2 and VH2 are from different immunoglobulins.

### Claim 6 (depends on 1)

The binding protein of claim 1, wherein the first and second binding domains are derived from different immunoglobulins.

### Claim 7 (depends on 1)

The binding protein of claim 1, wherein the first and second binding domains specifically bind different target molecules located on the same cell.

### Claim 8 (depends on 1)

The binding protein of claim 1, wherein the first and second binding domains specifically bind different target molecules located on physically distinct cells.

### Claim 9 (depends on 1)

The binding protein of claim 1, wherein at least one binding domain specifically binds a cell-free molecular target.

### Claim 10 (depends on 1)

The binding protein of claim 1, wherein at least one binding domain comprises a sequence selected from SEQ ID NO: 2, 4, 6, 103, 105, 107, and 109.

### Claim 11 (depends on 1)

The binding protein of claim 1, wherein the first and/or second peptide linker is 15 amino acids in length.

### Claim 12 (depends on 1)

The binding protein of claim 1, wherein the first and/or second peptide linker is 20 amino acids in length.

### Claim 13 (depends on 1)

The binding protein of claim 1, wherein the first and/or second peptide linker comprises a Gly4Ser sequence.

### Claim 14 (depends on 1)

The binding protein of claim 1, wherein the first and/or second peptide linker comprises the sequence Asp-Gly3-Ser-(Gly4Ser)2.

### Claim 15 (depends on 1)

The binding protein of claim 1, wherein the first and/or second peptide linker comprises the sequence (Gly4Ser)4.

### Claim 16 (depends on 1)

The binding protein of claim 1, wherein the immunoglobulin hinge domain is a hinge domain selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgE, IgA2, synthetic hinge and the hinge-like CH2 domain of IgM.

### Claim 17 (depends on 16)

The binding protein of claim 16, wherein the hinge domain is an IgG1 hinge domain.

### Claim 18 (depends on 17)

The binding protein of claim 17, wherein the hinge domain is a human IgG1 hinge domain with a mutation at one or two cysteine residues.

### Claim 19 (depends on 1)

The binding protein of claim 1, wherein the immunoglobulin CH2 domain is a IgG1 immunoglobulin CH2 domain.

### Claim 20 (depends on 1)

The binding protein of claim 1, wherein the immunoglobulin CH3 domain is a IgG1 immunoglobulin CH3 domain.

### Claim 21 (depends on 20)

The binding protein of claim 20, wherein the CH3 domain is truncated and comprises a C-terminal sequence selected from the group consisting of SEQ ID NO: 366-371.

### Claim 22 (depends on 1)

The binding protein of claim 1, wherein the binding protein does not comprise a CH1 domain.

### Claim 23 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker is at least 5 amino acids in length.

### Claim 24 (depends on 23)

The binding protein of claim 23, wherein the scorpion linker is between 5 and 45 amino acids in length.

### Claim 25 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker is resistant to proteolytic cleavage.

### Claim 26 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker comprises an amino acid sequence derived from an immunoglobulin hinge.

### Claim 27 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker comprises an amino acid sequence derived from an interdomain region of an immunoglobulin superfamily member.

### Claim 28 (depends on 27)

The binding protein of claim 27, wherein the immunoglobulin superfamily member is CD2, CD80, CD86, or CD22.

### Claim 29 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker comprises an amino acid sequence derived from a stalk region of a C-type lectin.

### Claim 30 (depends on 29)

The binding protein of claim 29, wherein the C-type lectin is selected from the group consisting of CD69, CD72, CD94, NKG2A, and NKG2D.

### Claim 31 (depends on 1)

The binding protein of claim 1, wherein the scorpion linker comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 287, 289, 297, 305, 307, 309, 310, 311, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 346, 373, 374, 375, 376, 377, 380, and 381.

### Claim 32 (depends on 1)

The binding protein of claim 1, wherein the first and/or second binding domains comprise chimeric, humanized, or human immunoglobulin variable domains.

### Claim 33 (depends on 1)

The binding protein of claim 1, wherein at least one binding domain specifically binds a target selected from a tumor antigen, a B-cell target, a TNF receptor superfamily member, a Hedgehog family member, a receptor tyrosine kinase, a proteoglycan-related molecule, a TGF-beta superfamily member, a Wnt-related molecule, a receptor ligand, a T-cell target, a Dendritic cell target, an NK cell target, a monocyte/macrophage cell target, a myeloid target, and an angiogenesis target.

### Claim 34 (depends on 1)

The binding protein of claim 1, wherein the binding protein is capable of cross-linking two or more targets.

### Claim 35 (depends on 1)

The binding protein of claim 1, wherein the first binding domain and the second binding domain are about 20-30 Å apart to about 150-180 Å apart.

### Claim 36 (depends on 1)

The binding protein of claim 1, wherein the first binding domain and the second binding domain are about 20-30 Å apart to less than about 50 Å apart.

### Claim 37 (depends on 1)

The binding protein of claim 1, wherein the first binding domain and the second binding domain are about 50 Å apart.

### Claim 38 (depends on 1)

The binding protein of claim 1, wherein the binding protein exhibits a binding affinity of less than 10−9 M or at least 10−6 M for at least one of the first binding domain and the second binding domain.

### Claim 39 (depends on 1)

A protein dimer comprising two multivalent binding proteins of claim 1.

### Claim 40 (depends on 1)

A nucleic acid encoding the binding protein of claim 1.

### Claim 41 (depends on 40)

A vector comprising the nucleic acid of claim 40.

### Claim 42 (depends on 40, 41)

A host cell comprising the nucleic acid of claim 40 or vector of claim 41.

### Claim 43 (depends on 1)

A composition comprising the binding protein of claim 1 and a pharmaceutically acceptable carrier.
